| 翻訳と辞書 |
| Gp100:209-217(210M) ： ウィキペディア英語版 |
Gp100:209-217(210M)
Gp100:209-217(210M) is a synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a methionine substitution at position 210.〔http://www.cancer.gov/drugdictionary/?CdrID=476335〕 It is often referred to as the ''gp100 cancer vaccine'' which can also include other peptides based on gp100 (for example gp100:280-288(288V) 〔http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=492712〕〔(【引用サイトリンク】title=Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma )〕).
==Clinical trials==
It gave good results in a trial for advanced melanoma when used in combination with interleukin-2.
Another trial against Ipilimumab in advanced melanoma suggested Ipilimumab may be better than the gp100 vaccine alone.〔http://www.genengnews.com/gen-news-highlights/bms-ipilimumab-proves-itself-in-metastatic-melanoma-patients/81243496/〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Gp100:209-217(210M)」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|